ano1

ANO1-IN-1, a selective ANO1 channel blocker, inhibited ANO1 and ANO2 with IC50 values of 2.56 μM and 15.43 μM, respectively.ANO1-IN-1 had a significant inhibitory effect on the proliferation of glioma cells.

ANO1-IN-4 (Compound 10bm) is a reversible inhibitor of the calcium-activated chloride channel transmembrane protein 16A (TMEM16A, also known as ANO1), with an IC50 of 0.030 µM. It demonstrates good metabolic stability in rat liver microsomes and can inhibit spontaneous contractions in isolated mouse ileum.

ANO1-IN-3 (Compound 3n) is a potent and selective inhibitor of ANO1, with an IC50 of 1.23 μM, and can induce apoptosis [1].

ANO1-IN-2 (Compound 10q) is a potent and selective ANO1 channel blocker with an IC50 value of 1.75 μM against ANO1 and 7.43 μM against ANO2, demonstrating significant anti-proliferative activity in glioblastoma cells [1].

The Anti-ANO1/TMEM16A Antibody is a CHO-expressed human-derived antibody targeting ANO1/TMEM16A. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Hemin (Hemin chloride) is a chlorinated iron-containing porphyrin, a heme oxygenase (HO)-1 inducer. Hemin has therapeutic activity in porphyrias by reducing heme deficiency in patients, thereby inhibiting δ-aminolevulinic acid synthetase activity through biochemical feedback.

T16Ainh-A01 is a potent inhibitor of TMEM16A Chloride channel, inhibiting TMEM16A-mediated chloride currents (IC50 of 1 µM),and functions as a calcium-activated chloride channel (CaCC).

T16A(inh)-B01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class B inhibitor.

T16A(inh)-C01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class C inhibitor.

T16A(inh)-D01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class D inhibitor.

Ani9 is a high selective blocker of Anoctamin1 (ANO1)/transmembrane protein 16A (TMEM16A) with an IC50 of 77 nM and can be used in studies about ANO1 and the treatment of ancer, hypertension, pain, diarrhea and asthma.

DFBTA is a highly effective and orally active inhibitor of ANO1, specifically the calcium-activated chloride channel anoctamin-1. It exhibits potent inhibitory activity, with an IC 50 of 24 nM. Notably, DFBTA demonstrates significant analgesic efficacy in treating inflammatory pain [1].

Kobusin, a bisepoxylignan compound isolated from Pnonobio biondii Pamp, demonstrates CFTR and CaCC chloride channel activation properties while exhibiting inhibitory effects on ANO1/CaCC channels.

Matairesinoside is a lignan extracted from the stem bark of Styrax japonica S. et Z, which is known to exhibit antibacterial and antioxidant properties while also functioning as a virus–cell fusion inhibitor. Matairesinoside acts as a potent inhibitor of TMEM16A, a novel target implicated in lung cancer progression, confirmed through molecular simulation and site-directed mutagenesis. Matairesinoside significantly reduces lung cancer cell growth, migration, and invasion while inducing apoptosis, with gene knockdown and overexpression demonstrating TMEM16A as the direct target and Western blot analysis elucidating the associated signaling pathways involved in tumor suppression.